Ann: Appendix 4E and Preliminary Final Report, page-6

Weak hands were milked @ $0.095

$3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department
of Defense to advance the development of Travelan to target key protective antigens of the major enteric
bacterial pathogens Campylobacter, Shigella and Entertoxigenic E. colistrains not present in the current
product formulation.

To be granted the $3.5M would suggest that NMRC are encouraged by what they saw in the CampETEC trail which treated 2 of the 3 components (Campylobacter and enterotoxigenic E. coli product) of the "Travelan+" product to be advanced by NMRC and WRAIR.

The CampETEC trail was done on the same dosing regime (3 a day) as the previous Phase 2 (Otto et al. 2011) where the attack rates were 73% and 86% with protective efficacy of 90.9% and 76.7%.

Positive CampETEC readout and those on the sideline will be left trying to catch a greasy pig